May
22
2:30 PM14:30

LPO inhibition for treatment of neurodegenerative diseases

Пленарный доклад: ИНГИБИРОВАНИЕ ЛИПИДНОГО ПЕРОКИСЛЕНИЯ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ Щепинов Михаил Компания Retrotope, Лос Альтос, Калифорния

Presentation by Mikhail Shchepinov, PhD

Chief Scientific Officer, Retrotope, Inc., Los Altos, CA, USA

View Event →
Mar
30
11:30 AM11:30

Undoing Aging 2019 - Counteracting oxidation via deuteration of lipids

Many of our cells decline with age in function and/or number as a result of spontaneous, destructive chemical reactions. One of the most problematic examples is Alzheimer's disease. A huge contributor to this process is spontaneous oxidation, which disrupts the structure and function of bioactive molecules as diverse as lipids, proteins and DNA.

View Event →
Feb
5
12:00 PM12:00

Adding neutrons to neurons: heavy handling of neurodegeneration

  • Florey Institute of Neuroscience (map)
  • Google Calendar ICS

Non-enzymatic lipid peroxidalion <LPO> is an ineluctable consequence of living with oxygen. This pernicious process damages membranes and generates a smorgasbord of toxic products while anti-oxidant defenses cannot cope. due to the chain reaction nature of LPO. A possible way to resolve the problem is to make PUFAs impervious to LPO. white not changing them chemically (well. almost). by deuterating bis-allylic positions to slow down the LPO chain through inhibition of the rate limiting initiation step LPO is a feature of numerous neuro-. mito- and retinal disorders as well as aging and by using the “reinforced" PUFA drugs benefits can be seen across a range of diseases, including Alzheimer's, Parkinson's, Huntington's, Friedreich’s ataxia, atherosclerosis etc. as the ongoing clinical trials indicate.

Presented by Misha Shchepinov, CSO and Founder of Retrotope, Inc. (USA)

View Event →
Feb
4
12:00 PM12:00

Adding neutrons to neurons: heavy handling of neurodegeneration

Non-enzymatic lipid peroxidalion <LPO> is an ineluctable consequence of living with oxygen. This pernicious process damages membranes and generates a smorgasbord of toxic products while anti-oxidant defenses cannot cope. due to the chain reaction nature of LPO. A possible way to resolve the problem is to make PUFAs impervious to LPO. white not changing them chemically (well. almost). by deuterating bis-allylic positions to slow down the LPO chain through inhibition of the rate limiting initiation step LPO is a feature of numerous neuro-. mito- and retinal disorders as well as aging and by using the “reinforced" PUFA drugs benefits can be seen across a range of diseases, including Alzheimer's, Parkinson's, Huntington's, Friedreich’s ataxia, atherosclerosis etc. as the ongoing clinical trials indicate.

Presented by Misha Shchepinov, CSO and Founder of Retrotope, Inc. (USA)

View Event →
Nov
10
1:30 PM13:30

Lipid Peroxidation-Resistant Polyunsaturated Fatty Acids (PUFA)

Founder and Chief Scientist Misha Shchepinov will present:

PUFAs are essential nutrients vital for biological, particularly mitochondrial and neuronal, membranes. Unlike any other type of oxidative stress-related damage, lipid peroxidation is a chain process which, once initiated, can damage thousands of PUFA residues before the reaction is terminated. The rate limiting step of the process is hydrogen abstraction at the bis-allylic (between double bonds) site. Antioxidants are inefficient for various reasons. A novel approach employs deuteration of PUFAs at the bis-allylic positions to stops lipid peroxidation by inhibiting the rate limiting step (hydrogen abstraction) due to the isotope effect. Numerous cell culture and animal studies, as well as Phase I in humans, support the role of LPO in neurological and other diseases, and offer a novel therapeutical intervention.

View Event →
Sep
15
5:00 PM17:00

Understanding Energy for a Cure Symposium

  • USF Sam and Martha Gibbons Alumni Center (map)
  • Google Calendar ICS

Retrotope will be a presenter at this Symposium.

"Join USF Ataxia Research Center leadership, Dr. Theresa Zesiewicz MD., FAAN, along with FARA Executive Director, Jennifer Farmer and President, Ronald Bartek for a special interactive symposium focused on advancing therapeutic approaches. The symposium will feature updates for ongoing clinical trials along with drug discovery efforts targeting the root cause of this genetic disease. Top researchers will share insights into emerging treatments for Friedreich’s Ataxia. A special panel of individuals living with FA will also share their experiences and perspectives."

View Event →
Jun
15
10:30 AM10:30

13th International Conference on Wearable and Implantable Body Sensor Networks (BSN 2016)

  • UCSF Mission Bay Conference Center (map)
  • Google Calendar ICS

Poster session presentation by Dr. Robert LeMoyne on "Wearable Body and Wireless Inertial Sensors for Machine Learning Classification of Gait for People with Friedreich’s Ataxia"

Authors: Robert LeMoyne, Frederic Heerinckx, Tanya Aranca, Robert De Jager, Theresa Zesiewicz, Harry J. Saal

 

 

 

View Event →
Mar
25
to Mar 28

International Ataxia Research Conference 2015

Retrotope, Inc., an emerging, clinical stage degenerative disease therapeutic company, gave a presentation at the International Ataxia Research Conference.  The talk entitled: “An upcoming clinical trial testing the safety and efficacy of a stabilized polyunsaturated fatty acid in Friedreich’s ataxia” elucidated the company’s progress towards an Investigational New Drug (IND) application for the fatal, orphan disease, Friedreich’s ataxia (FRDA).   Currently, there is no approved therapy for FRDA. See the News section for further details.

 

View Event →